Medications for Pneumocystis Pneumonia

26 results

  • atovaquone

    (Atovaquone)
    Camber Pharmaceuticals, Inc.
    Atovaquone oral suspension is indicated for the prevention and treatment of mild-to-moderate Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). Its use is limited to this population and condition.

  • atovaquone

    (Atovaquone)
    Bionpharma Inc.
    Atovaquone oral suspension is indicated for preventing and treating mild-to-moderate Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents (≥13 years) who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). Its use is limited to mild-to-moderate cases, with no studies for severe PCP or TMP-SMX failures.

  • atovaquone

    (Atovaquone)
    PAI Holdings, LLC
    Atovaquone oral suspension is indicated for the prevention and treatment of mild-to-moderate Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents (aged 13 and older) who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). Limited clinical experience exists for severe PCP cases or treatment failures with TMP-SMX.

  • atovaquone

    (Atovaquone)
    AvPAK
    Atovaquone oral suspension is indicated for the prevention and treatment of mild-to-moderate Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). Its use is limited to mild-to-moderate cases.

  • atovaquone

    (Atovaquone)
    Avion Pharmaceuticals, LLC
    Atovaquone oral suspension is indicated for the prevention and treatment of mild-to-moderate Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents (age 13 and older) who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). Its use is limited to cases categorized as mild-to-moderate PCP.

  • atovaquone

    (atovaquone)
    NorthStar RxLLC
    Atovaquone oral suspension is indicated for the prevention and treatment of mild-to-moderate Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents (13 years and older) who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). Efficacy for severe PCP or in treatment failures with TMP-SMX has not been established.

  • atovaquone

    (Atovaquone)
    Kesin Pharma
    Atovaquone oral suspension is indicated for the prevention and treatment of mild-to-moderate Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents (aged 13 and older) who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). Its use is limited to mild-to-moderate cases and unstudied for severe PCP.

  • atovaquone oral suspension

    (Atovaquone)
    KVK-Tech Inc
    Atovaquone oral suspension is indicated for the prevention and treatment of mild-to-moderate Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). Efficacy in severe cases or those failing TMP-SMX therapy is not established.

  • mepron

    (atovaquone)
    GlaxoSmithKline LLC
    MEPRON is indicated for the prevention and treatment of mild-to-moderate Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents (ages 13+) who cannot tolerate trimethoprim-sulfamethoxazole. Its use for more severe cases of PCP or in patients failing TMP-SMX therapy has not been studied.

  • pentam 300

    (PENTAMIDINE ISETHIONATE)
    Fresenius Kabi USA, LLC
    Pentam 300 (pentamidine isethionate for injection) is indicated for the treatment of pneumonia caused by *Pneumocystis carinii*.